Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Familial Adenomatous Polyposis
Interventions
DRUG

Encapsulated Rapamycin (eRapa)

eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

Trial Locations (4)

43210

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

48109

Michigan Medicine, Ann Arbor

78229

UT Health, San Antonio

All Listed Sponsors
collaborator

Cancer Insight, LLC

INDUSTRY

collaborator

Biodexa Pharmaceuticals

INDUSTRY

lead

Rapamycin Holdings Inc.

INDUSTRY